GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Bluejay Diagnostics
Bluejay Diagnostics is a company developing rapid diagnostic tests. Its stock price is a bet on the success of its Symphony platform. The chart reflects high volatility and dependence on news about clinical data and commercialization.
Share prices of companies in the market segment - Medanalysis
Bluejay Diagnostics develops diagnostic tests for rapid patient assessment in emergency departments, specifically to determine the risk of sepsis. We've categorized it as a "Medanalysis" company. The chart below shows how the market views the rapid medical diagnostics sector.
Broad Market Index - GURU.Markets
Bluejay Diagnostics is a healthcare company developing diagnostic tests to quickly determine the severity of illnesses in patients in emergency departments. It is a component of the GURU.Markets index. The chart below represents the market. See how this stock compares to the diagnostics sector.
Change in the price of a company, segment, and market as a whole per day
BJDX - Daily change in the company's share price Bluejay Diagnostics
For Bluejay Diagnostics, Inc., a medical diagnostics company, daily volatility reflects sensitivity to news about the development and approval of its tests. This metric is an important element in risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Medanalysis
Bluejay Diagnostics develops rapid diagnostic tests for conditions requiring emergency care, such as sepsis. The rapid diagnostics market is competitive and innovative. The chart below shows the volatility in this niche, allowing you to compare BJDX's performance with other companies.
Daily change in the price of a broad market stock, index - GURU.Markets
Bluejay Diagnostics is a company specializing in medical diagnostics. The company's shares react to news of its tests being accepted by the medical community. This specific volatility, driven by medical innovation, feeds into the overall market movement.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Bluejay Diagnostics
Bluejay Diagnostics' year-to-date performance is the story of its rapid sepsis diagnostic test. Its 12-month market cap depends entirely on progress in clinical trials and FDA approval. The success of its platform could offer doctors a critical tool for rapidly diagnosing this deadly condition.
Annual dynamics of market capitalization of the market segment - Medanalysis
Bluejay, a diagnostic testing company, is betting on medical innovation. Its performance relative to the sector will reveal how much investors believe in its ability to commercialize its unique technology and secure regulatory approval.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Bluejay Diagnostics is a medical technology startup whose growth depends on the success of its diagnostic platform. Its performance relative to the market reflects investors' assessment of the potential of its tests. It's a long and risky journey from development to regulatory approval and commercialization.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Bluejay Diagnostics
Bluejay is a medical device company developing rapid diagnostic tests. Its monthly performance reflects progress toward FDA approval for its sepsis test. Updates on regulatory approval and trial data are key.
Monthly dynamics of market capitalization of the market segment - Medanalysis
The market for rapid diagnostics for critical conditions such as sepsis is a key area of medicine. The dynamics of this sector, shown in the graph, reflect the need for fast and accurate tests. Companies like Bluejay Diagnostics are developing in this area.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Bluejay Diagnostics is an early-stage company developing rapid diagnostic tests. Its shares represent a venture bet on the success of this medical technology. Its performance is completely detached from market trends and is driven by news about the progress of clinical trials and regulatory approvals.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Bluejay Diagnostics
Shares of Bluejay Diagnostics, a company developing rapid diagnostic tests, are extremely volatile. Weekly price movements depend entirely on news about the progress of clinical trials and the path to commercialization of their patient triage product. The chart below shows how short-term scientific events influence the stock.
Weekly dynamics of market capitalization of the market segment - Medanalysis
Bluejay Diagnostics develops rapid diagnostic tests. These products have enormous potential, but market penetration requires regulatory approval and medical acceptance. The chart below shows how news about clinical validation and regulatory decisions impact the company's stock, causing it to move independently of its sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Bluejay Diagnostics is a medical technology startup. This chart compares its weekly volatility with the market. It shows how its stock, like other early-stage companies, is driven by news about regulatory approvals and research progress, rather than by overall market trends.
Market capitalization of the company, segment and market as a whole
BJDX - Market capitalization of the company Bluejay Diagnostics
Bluejay Diagnostics' market capitalization is the valuation of its rapid in-office diagnostic testing platform. The company's value at the development stage depends on its ability to secure regulatory approval and demonstrate the advantages of its analyzer. The chart illustrates the long and risky path to commercialization of medical technology.
BJDX - Share of the company's market capitalization Bluejay Diagnostics within the market segment - Medanalysis
Bluejay Diagnostics' market share in the medical technology sector is based on its rapid point-of-care diagnostic platform. Its market share is based on its pioneering product for triaging patients at risk for sepsis, which could save lives and reduce the burden on hospitals.
Market capitalization of the market segment - Medanalysis
Here's a chart of the total market capitalization of companies engaged in rapid diagnostics. Bluejay Diagnostics is one of the players in this field. The graph shows how the market values technologies that can speed up diagnosis and improve treatment outcomes.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart depicts the market value of rapid at-home diagnostics. Bluejay Diagnostics' market cap is a bet on its patient triage testing system. The line shows how a small medical device company is fighting for market share, promising to revolutionize primary care.
Book value capitalization of the company, segment and market as a whole
BJDX - Book value capitalization of the company Bluejay Diagnostics
The graph below shows the scientific foundation of Bluejay Diagnostics. Its line represents the value of the intellectual property for the Symphony™ diagnostic platform for rapid triage of patients at risk for sepsis. An increase in the graph indicates progress in the development of this critical medical test.
BJDX - Share of the company's book capitalization Bluejay Diagnostics within the market segment - Medanalysis
Bluejay Diagnostics's core assets are its R&D centers and equipment for developing diagnostic tests for emergency medicine. The chart shows the company's share of this scientific infrastructure, which forms the physical basis for creating rapid and accurate tests for critical conditions.
Market segment balance sheet capitalization - Medanalysis
Against the backdrop of the capital-intensive pharmaceutical industry, Bluejay Diagnostics has chosen the diagnostics path. Its business requires a unique yet focused resource base—production lines for its tests. The chart illustrates the scale of the industry in which Bluejay occupies its high-tech niche.
Book value of all companies included in the broad market index - GURU.Markets
Bluejay Diagnostics develops rapid tests for diagnosing conditions requiring immediate intervention, such as sepsis. The company's assets are not hospitals, but rather the technology and manufacturing capabilities to create these "pocket labs." The graph will show the impact of this innovation on diagnostics.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Bluejay Diagnostics
Bluejay Diagnostics is a medical diagnostics company. Its market value is derived from its technology and its potential to create a rapid and accurate test for diagnosing conditions requiring emergency care.
Market to book capitalization ratio in a market segment - Medanalysis
Bluejay Diagnostics develops rapid diagnostic tests for conditions requiring urgent care. Its value depends on the success of its diagnostic platform. This chart shows how its market valuation, reflecting the commercial potential of its tests, relates to its tangible assets.
Market to book capitalization ratio for the market as a whole
Bluejay Diagnostics develops rapid diagnostic tests for conditions requiring urgent medical attention. This chart shows the market sentiment for their Symphony technology platform and the potential of future products. Price movements are heavily dependent on the success of clinical trials and regulatory approvals.
Debts of the company, segment and market as a whole
BJDX - Company debts Bluejay Diagnostics
Bluejay Diagnostics, a development-stage company, is using raised capital to develop its diagnostic test for determining patients' triage status. This chart shows how the company is funding R&D, engineering, and clinical trial preparation to bring its innovative medical device to market.
Market segment debts - Medanalysis
Bluejay Diagnostics develops rapid diagnostic tests for conditions requiring urgent care. Bringing new medical diagnostic devices to market is a lengthy and expensive process. This chart shows how the company's debt policy reflects its stage of development and capital requirements for clinical trials and regulatory approval.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Bluejay Diagnostics
SciSparc is a pharmaceutical company specializing in developing cannabinoid-based drugs for the treatment of central nervous system disorders. This is a cutting-edge but complex field. This chart shows how the company funds its clinical research, reflecting its commitment to the medicinal potential of these compounds.
Market segment debt to market segment book capitalization - Medanalysis
Bluejay Diagnostics develops diagnostic tests for the rapid detection of triage conditions in emergency settings. This chart compares its debt load to the overall market capitalization of the entire sector. It shows how the early-stage company is funding its research and regulatory approval process for its flagship product.
Debt to book value of all companies in the market
Bluejay Diagnostics develops diagnostic tests for rapid patient assessment, such as sepsis. In the medical diagnostics sector, speed and accuracy are crucial. This graph of total market debt helps understand the financial environment in which the company is raising capital to complete clinical trials and bring its life-saving tests to market.
P/E of the company, segment and market as a whole
P/E - Bluejay Diagnostics
For Bluejay Diagnostics, a development-stage medical device company, the P/E ratio is irrelevant. It has no profit. Its valuation on this chart is arbitrary. Its true value is determined by investors' faith in the potential of its diagnostic platform and its success in obtaining regulatory approval.
P/E of the market segment - Medanalysis
Bluejay Diagnostics is a company specializing in the development of diagnostic tests for emergency medicine. Its flagship product, Symphony, is designed to rapidly assess the risk of kidney failure in critically ill patients. This chart shows the average rating for the medical analysis sector, reflecting the market's appreciation for technologies that facilitate rapid decision-making at the bedside.
P/E of the market as a whole
Bluejay Diagnostics is developing a rapid diagnostic platform based on whole blood samples for use in emergency settings. Its first product is aimed at triaging patients with suspected appendicitis. This risk appetite chart helps understand how investors value companies developing innovative diagnostic tests.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Bluejay Diagnostics
Bluejay Diagnostics develops rapid diagnostic tests for conditions requiring urgent medical attention. This chart shows market expectations regarding the commercial success of its diagnostic platform. Future revenue depends on regulatory approval and clinical adoption of the tests.
%20P%2FE%20Bluejay%20Diagnostics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Bluejay-Diagnostics&v=1772553689920 "Chart of the company's future (projected) P/E Bluejay Diagnostics")
Future (projected) P/E of the market segment - Medanalysis
Bluejay Diagnostics develops diagnostic tests for critical care, such as sepsis detection. This chart compares the company's future profitability expectations with those of the medtech sector. It shows how much investors believe in the clinical and commercial value of its flagship test and its potential to become a standard in hospitals.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Medanalysis&v=1772553689941 "Future (projected) P/E graph of the market segment - Medanalysis")
Future (projected) P/E of the market as a whole
Bluejay Diagnostics develops rapid diagnostic tests for conditions requiring urgent care, such as triaging patients with chest pain. The rollout of their products depends on regulatory approval and hospital adoption. The overall economic backdrop, illustrated in this graph, impacts healthcare budgets and the speed of adoption of innovative diagnostic solutions.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772553689960 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Bluejay Diagnostics
Bluejay Diagnostics is a medical diagnostics company developing rapid tests for emergency care. Its financial health is determined by expenses on product development and clinical validation. This chart shows the company's path to commercialization, with future revenue dependent on regulatory approval and acceptance of its tests by the medical community.
Profit of companies in the market segment - Medanalysis
Bluejay Diagnostics develops rapid diagnostic tests for conditions requiring urgent care, such as sepsis. This graph, showing overall sector profitability, reflects the importance of rapid diagnostics. Bluejay's ability to create an accurate and rapid test that can be used at the patient's bedside could save lives and have a profound impact on the entire industry.
Overall market profit
Bluejay Diagnostics develops rapid diagnostic tests for conditions requiring urgent medical attention, such as sepsis. Rapid and accurate diagnostics can save lives and reduce treatment costs. The company's success depends on the accuracy of its tests and their implementation in clinical practice, not on the overall economic situation.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Bluejay Diagnostics
Bluejay Diagnostics is developing a diagnostic platform for rapidly identifying triage conditions in patients. The future revenue projections you see depend on the successful commercialization of their tests. Analysts are evaluating the product's potential to improve diagnostics in emergency departments and achieve FDA approval.
%20profit%20of%20the%20company%20Bluejay%20Diagnostics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Bluejay-Diagnostics&v=1772553690020 "Graph of future (projected) profit of the company Bluejay Diagnostics")
Future (predicted) profit of companies in the market segment - Medanalysis
Bluejay Diagnostics is developing a diagnostic platform for rapidly determining the triage status of patients at risk for kidney failure. This graph reflects revenue expectations for the entire medical analytics sector. It allows one to assess how the company's technology, targeting a critical area of medicine, compares to overall diagnostic trends.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Medanalysis&v=1772553690055 "Graph of future (predicted) profits of companies in a market segment - Medanalysis")
Future (predicted) profit of the market as a whole
Bluejay Diagnostics develops rapid diagnostic tests for conditions requiring urgent care. Demand for such products is driven by medical necessity. However, the speed of implementation of new diagnostic platforms in hospitals depends on their budgets, which, in turn, depend on the overall economic situation, as reflected in this graph.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772553690096 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Bluejay Diagnostics
Bluejay Diagnostics develops diagnostic tests for the rapid detection of conditions requiring urgent care, such as sepsis. This metric, which correlates its market capitalization with virtually zero revenue, reflects the valuation of its technology. It demonstrates investors' belief that its product can speed up diagnostics and save lives, leading to future sales.
P/S market segment - Medanalysis
Bluejay Diagnostics develops diagnostic tests for use in emergency care settings. Its flagship product is designed to quickly determine the need for hospitalization during patient triage. This chart shows how investors estimate revenue in the medical diagnostics sector, reflecting expectations for the commercialization of Bluejay's tests and their impact on the healthcare system.
P/S of the market as a whole
Bluejay Diagnostics develops and commercializes diagnostic tests for rapid patient assessment in emergency settings. Its flagship test is designed to determine the triage category for sepsis. This chart helps understand how the market values companies in the early-stage medical diagnostics sector.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Bluejay Diagnostics
Bluejay Diagnostics is developing a diagnostic platform for rapid patient assessment in emergency settings. This chart shows investors' estimates of its potential future revenue from test sales. It reflects market confidence that its technology will be adopted and become standard in emergency departments.
%20P%2FS%20Bluejay%20Diagnostics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Bluejay-Diagnostics&v=1772553690186 "The graph of the company's future (projected) P/S Bluejay Diagnostics")
Future (projected) P/S of the market segment - Medanalysis
Bluejay Diagnostics develops diagnostic tests for rapid patient assessment, specifically a test for acute kidney injury. The chart shows the average estimated future revenue for the medical diagnostics sector. It helps understand how the market perceives the potential of Bluejay's technology to improve treatment outcomes and its commercial prospects in the diagnostics market.
%20P%2FS%20market%20segment%20graph%20-%20Medanalysis&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Medanalysis&v=1772553690226 "Future (projected) P/S market segment graph - Medanalysis")
Future (projected) P/S of the market as a whole
Bluejay Diagnostics (BJDX) develops rapid diagnostic tests for conditions requiring urgent medical attention. Their success depends on the accuracy of their tests and their implementation in clinical practice. This schedule is not relevant to their business, which is driven by the needs of emergency medicine, not by general economic trends.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772553690231 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Bluejay Diagnostics
Bluejay Diagnostics is developing innovative rapid diagnostic tests. The company does not yet have stable sales revenue. Future growth will depend on successful regulatory approval and the commercial launch of its diagnostic platform for detecting critical illnesses such as sepsis.
Sales of companies in the market segment - Medanalysis
Bluejay Diagnostics is a company developing rapid diagnostic tests for conditions requiring emergency medical care. Its first product is aimed at triaging patients with suspected appendicitis. Future revenue growth will depend on the successful launch of this and other diagnostic tests.
Overall market sales
Bluejay Diagnostics, Inc. is developing a platform for rapid point-of-care diagnostics. The company's success will depend on approvals and the implementation of its tests in hospitals. This timeline, reflecting the overall economic situation, influences healthcare system budgets and their willingness to invest in new diagnostic technologies that can speed decision-making and improve care.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Bluejay Diagnostics
Bluejay Diagnostics develops diagnostic tests for rapid patient assessment in emergency settings. The company's future revenue depends on regulatory approval and hospital adoption of its tests. This graph reflects analysts' long-term expectations for the rapid diagnostics market and the potential of its platform.
%20sales%20of%20the%20company%20Bluejay%20Diagnostics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Bluejay-Diagnostics&v=1772553690430 "Schedule of future (projected) sales of the company Bluejay Diagnostics")
Future (projected) sales of companies in the market segment - Medanalysis
Bluejay Diagnostics develops rapid diagnostic tests for conditions requiring urgent medical attention, such as sepsis. This chart shows the outlook for the healthcare analytics sector, reflecting hospitals' need for fast and accurate diagnostic tools to improve outcomes for critically ill patients.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Medanalysis&v=1772553690554 "Schedule of future (projected) sales of companies in the market segment - Medanalysis")
Future (projected) sales of the market as a whole
This chart reflects healthcare costs that are important to Bluejay Diagnostics. The company develops rapid diagnostic tests. The introduction of new diagnostic platforms into medical practice depends on clinic budgets and their desire to improve efficiency, which is stimulated by a stable economy.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772553690677 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Bluejay Diagnostics
Bluejay Diagnostics is developing a diagnostic platform for rapid triage status determination in emergency settings. This chart reflects the company's financial performance during the product development phase. Future profitability is entirely dependent on successful clinical validation, FDA approval, and commercialization in hospitals.
Market segment marginality - Medanalysis
Bluejay Diagnostics develops diagnostic tests for the early detection of life-threatening diseases such as sepsis. The company's profitability will depend on obtaining regulatory approvals and the clinical adoption of its tests. This chart shows the average profitability in the sector, helping to assess the commercial potential of its innovative diagnostic solutions.
Market marginality as a whole
Bluejay Diagnostics develops diagnostic tests for emergency medical care. Commercialization of its products depends on approvals and market acceptance. This graph, reflecting the overall state of the economy, impacts healthcare system budgets. It determines how quickly hospitals can implement new, albeit more effective, diagnostic platforms.
Employees in the company, segment and market as a whole
Number of employees in the company Bluejay Diagnostics
Bluejay Diagnostics develops rapid diagnostic tests for conditions requiring urgent medical attention. This graph shows a compact team focused on research, development, and clinical trials. A small staff is typical for a pre-commercialization diagnostic company, where technology is its core value.
Share of the company's employees Bluejay Diagnostics within the market segment - Medanalysis
Bluejay Diagnostics is developing a diagnostic platform for the rapid detection of triage markers in emergency medicine. This chart shows the company's share of the total number of specialists in the rapid diagnostics sector. This reflects its focus on solving critical problems in time-sensitive settings, where every minute counts.
Number of employees in the market segment - Medanalysis
Bluejay Diagnostics develops diagnostic tests for rapid patient triage in emergency departments. This chart, illustrating employment in the medical analytics sector, is indicative. The growing number of rapid diagnostic specialists indicates a high demand from hospitals for tools to quickly and accurately assess patients' conditions.
Number of employees in the market as a whole
Bluejay Diagnostics develops rapid diagnostic tests for critical conditions. The implementation of new medical technologies depends on healthcare funding. This total employment chart reflects the economic base that supports this funding. A stable labor market ensures a flow of funds to insurance funds, allowing hospitals to purchase modern equipment.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Bluejay Diagnostics (BJDX)
Bluejay Diagnostics develops rapid diagnostic tests, such as those for sepsis detection. In the medical diagnostics sector, this metric reflects the value of the technology. The company's value lies in its patents for a life-saving testing platform. A small R&D team generates intellectual property with a high market value.
%20of%20the%20company%20Bluejay%20Diagnostics%20(BJDX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Bluejay-Diagnostics-BJDX&v=1772553690930 "Chart of market capitalization per employee (in thousands of dollars) of the company Bluejay Diagnostics (BJDX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Medanalysis
Bluejay Diagnostics develops rapid diagnostic tests for emergency conditions. In the medical device industry, value is often created through patents and unique technology, not through a large workforce. This metric allows us to see the market premium for innovation per employee, which distinguishes developers from medical device distributors.
%20by%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Medanalysis&v=1772553690958 "Market capitalization per employee (in thousands of dollars) by market segment - Medanalysis")
Market capitalization per employee (in thousands of dollars) for the overall market
Bluejay Diagnostics develops diagnostic tests for rapid patient assessment in critical situations. In medical diagnostics, value is determined by speed and accuracy. This metric demonstrates how the market perceives the company's technology's potential to save lives and optimize hospital operations, where a small team creates a product with a big impact.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772553691064 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Bluejay Diagnostics (BJDX)
Bluejay Diagnostics develops rapid point-of-care diagnostic tests, specifically the Symphony test for determining the need for hospitalization for pediatric ear infections. This is R&D in medtech. This chart shows the company's capital burn rate: how much the company spends (negative profit) on each employee to complete development and obtain FDA approval.
%20Chart%20Bluejay%20Diagnostics%20(BJDX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Bluejay-Diagnostics-BJDX&v=1772553691099 "Company Profit Per Employee (in thousands of dollars) Chart Bluejay Diagnostics (BJDX)")
Profit per employee (in thousands of dollars) in the market segment - Medanalysis
Bluejay Diagnostics develops rapid diagnostic tests. While the company is in the development and regulatory approval stages, it may not achieve stable profitability. This chart helps assess how effectively it is managing its finances as it moves toward commercialization. This indicator's dynamics will depend on the successful launch of its products.
%20in%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Medanalysis&v=1772553691145 "Chart of profit per employee (in thousands of dollars) in the market segment - Medanalysis")
Profit per employee (in thousands of dollars) for the market as a whole
Bluejay Diagnostics (BJDX) is developing the Symphony platform for rapid point-of-care diagnostics of diseases such as sepsis. It is a MedTech company in the R&D stage. It is non-profitable. Its staff consists of scientists and engineers. This metric is negative and reflects the "cost" of one employee creating the future diagnostic technology.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772553691204 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Bluejay Diagnostics (BJDX)
Bluejay Diagnostics is developing rapid diagnostic tests for conditions requiring urgent care. This graph, prior to commercial launch, shows potential. Successful implementation of their tests in hospitals could lead to significant revenue growth for a small team.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Bluejay-Diagnostics-BJDX&v=1772553691278 "Sales chart per company employee Bluejay Diagnostics (BJDX)")
Sales per employee in the market segment - Medanalysis
Bluejay Diagnostics develops point-of-care diagnostic tests, starting with a triage test for ear pain patients. This is an R&D business. This chart reflects their clinical stage. The productivity of their team of scientists and physicians is measured not by sales, but by their ability to obtain FDA approval for their first product.
Sales per employee for the market as a whole
GRAIL (GRAL) is a life sciences company whose mission is early cancer detection with a single blood test (the "Gallbladder" test). This is a revolutionary diagnostic technology. The company is currently in the commercialization phase and conducting large-scale clinical trials. This graph reflects their significant investment in R&D and marketing. This figure will grow as their tests gain wider acceptance.
Short shares by company, segment and market as a whole
Shares shorted by company Bluejay Diagnostics (BJDX)
Bluejay Diagnostics (BJDX) is a development-stage company developing rapid diagnostic tests. This chart shows the volume of short positions. Short positions reflect high risk: bears are betting that the company's test will not be approved by the FDA or will prove inaccurate.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Bluejay-Diagnostics-BJDX&v=1772553691394 "Short Shares Chart for the Company Bluejay Diagnostics (BJDX)")
Shares shorted by market segment - Medanalysis
Bluejay Diagnostics (BJDX) develops diagnostic tests for rapid patient assessment (e.g., chest pain triage). The chart below shows the overall short position in the medical diagnostics sector. It reflects investors' confidence in the ability of these new tests to penetrate the conservative medical market.
Shares shorted by the overall market
Bluejay Diagnostics develops rapid diagnostic tests, specifically for triaging patients with traumatic brain injuries. This chart illustrates the general fear. When investors are pessimistic, they are skeptical of new medical technology devices. They fear slow market adoption and problems with insurance reimbursement, which puts pressure on BJDX shares.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Bluejay Diagnostics (BJDX)
This oscillator for Bluejay Diagnostics is a barometer of the rapid diagnostics market. The company is developing a test (Symphony) for the rapid diagnosis of sepsis in the intensive care unit. "Overheating" (above 70) occurs due to the anticipation of data or FDA approval. Development delays and a high risk of failure to obtain approval lead to "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Bluejay-Diagnostics-BJDX&v=1772553691761 "RSI 14 indicator chart for the company's stock Bluejay Diagnostics (BJDX)")
RSI 14 Market Segment - Medanalysis
Bluejay Diagnostics is a company developing rapid diagnostics (point-of-care). Their flagship test, Symphony, is designed to quickly triage patients with abdominal pain (suspected appendicitis). This chart reflects the overall sentiment in the medical testing and diagnostics sector and helps assess how the market views the industry as a whole.
RSI 14 for the overall market
Bluejay Diagnostics (BJDX) develops diagnostic tests for rapid patient assessment. Like many early-stage medical device companies, it relies on investment. This market "temperature" chart shows when investors are risk-seeking (euphoria) or risk-averse (panic). This directly impacts the availability and cost of capital required for BJDX to bring its products to market.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast BJDX (Bluejay Diagnostics)
Bluejay (BJDX) develops rapid diagnostic tests (Symphony) for emergency departments. This chart shows the average price target from analysts. It reflects their speculative assessment of the likelihood of the company's technology receiving FDA approval and being adopted by hospitals within the next 12 months.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-BJDX-Bluejay-Diagnostics&v=1772553692133 "A chart showing analyst consensus forecasts for the expected stock price. BJDX (Bluejay Diagnostics)")
The difference between the consensus estimate and the actual stock price BJDX (Bluejay Diagnostics)
Bluejay Diagnostics (BJDX) is a medical technology company developing rapid point-of-care tests for early diagnostics, specifically for sepsis patient triage. This chart shows the difference between the current price and the analyst consensus forecast. It reflects their confidence in the approval and adoption of their diagnostic platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-BJDX-Bluejay-Diagnostics&v=1772553692167 "A chart showing the difference between the consensus forecast and the actual stock price. BJDX (Bluejay Diagnostics)")
Analyst consensus forecast for stock prices by market segment - Medanalysis
Bluejay Diagnostics is a medical device company developing point-of-care tests for the rapid diagnosis of conditions requiring emergency care (such as sepsis). This chart shows analysts' overall expectations for the medical testing sector. It reflects whether experts believe the market for rapid, point-of-care diagnostics will grow.
Analysts' consensus forecast for the overall market share price
Bluejay Diagnostics (BJDX) is a clinical-stage biotech company. They are developing a rapid diagnostic platform (test) to assist doctors, for example, in treating ear infections in children. This is a high-risk scientific endeavor. This chart shows the overall risk appetite in the market. It is an indicator of the "open" or "closed" funding window for speculative biotechs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Bluejay Diagnostics
Bluejay Diagnostics is an R&D company working on a critical problem: rapid diagnostic testing (triage) in emergency departments. Their platform (Symphony) targets appendicitis. This chart is purely an R&D barometer. It doesn't reflect revenue, but rather a speculative assessment of their progress toward FDA approval, their clinical data, and their chances of commercialization.
AKIMA Market Segment Index - Medanalysis
Bluejay Diagnostics develops rapid point-of-care tests for medical diagnostics, such as rapid detection of sepsis. Their goal is to provide doctors with answers in minutes, not hours. This chart compares their composite index to the sector, demonstrating how their approach to rapid medical analytics outperforms the competition.
The AKIM Index for the overall market
Bluejay Diagnostics is a medtech company developing rapid point-of-care tests for patient triage, such as sepsis. This chart, reflecting the market average, provides context. It helps assess how this diagnostic landscape compares to overall macroeconomic trends and the demand for efficiency in hospitals.
